View:
Download DOC
Download PDF
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
McLoughlin Dennis
(Last) (First) (Middle)
C/O PACIRA PHARMACEUTICALS, INC.
5 SYLVAN WAY, SUITE 300
(Street)
PARSIPPANY NJ 07054
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/29/2018 		3. Issuer Name and Ticker or Trading Symbol
Pacira Pharmaceuticals, Inc. [ PCRX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 14,833(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (2) 07/03/2028 Common Stock 20,000 33.1 D
Stock Option (Right to Buy) (2) 06/13/2028 Common Stock 47,250 38.35 D
Stock Option (Right to Buy) (2) 06/14/2027 Common Stock 6,000 44.2 D
Stock Option (Right to Buy) (2) 06/02/2027 Common Stock 10,000 44.1 D
Stock Option (Right to Buy) (2) 02/02/2027 Common Stock 3,000 41.9 D
Stock Option (Right to Buy) (2) 12/07/2026 Common Stock 6,000 32.35 D
Stock Option (Right to Buy) (2) 06/15/2026 Common Stock 2,400 40.34 D
Stock Option (Right to Buy) (2) 06/03/2025 Common Stock 3,500 79.43 D
Stock Option (Right to Buy) (3) 01/03/2024 Common Stock 10,623 56.32 D
Explanation of Responses:
1. Includes 11,162 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 437 restricted stock units that vest on June 3, 2019, (ii) 600 restricted stock units that vest in two equal annual installments on June 3, 2019 and June 3, 2020, (iii) 2,250 restricted stock units that vest in three equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021, and (iv) 7,875 restricted stock units that vest in four equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021 and June 3, 2022, in each case provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
2. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
3. The stock options are fully vested.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact 09/07/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

I, Dennis McLoughlin, hereby authorize and designate each of Charles A.
Reinhart, III, Kristen Williams and Ned Prusse, signing singly, as
my true and lawful attorney-in-fact to:

	(1)	execute for and on my behalf, in my capacity as an officer
and/or director of Pacira Pharmaceuticals, Inc. and its affiliates (the
"Company"), the Form ID and Forms 3, 4 and 5 in accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act") and the rules and regulations promulgated thereunder;

	(2)	do and perform any and all acts for and on my behalf which
may be necessary or desirable to complete and execute any such Form ID or
Form 3, 4 or 5 and timely file such form with the Securities and Exchange
Commission, any stock exchange or similar authority; and

	(3)	take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-fact, may be
to my benefit, in my best interest, or legally required of me, it being
understood that the statements executed by such attorney-in-fact on my
behalf pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

	I hereby further grant to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as
I might or could do if personally present, with full power of substitutes
or revocation, hereby ratifying and confirming all that such attorney-in
fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and
the rights and powers herein granted.  I hereby acknowledge that the
foregoing attorneys-in-fact, in serving in such capacity at my request,
are not assuming, nor is the Company assuming, any of my responsibilities
to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until
I am no longer required to file the Form ID or Forms 3, 4 and 5 with
respect to my holdings of and transactions in securities issued by the
Company, unless earlier revoked by me in a signed writing delivered to
the foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, I have caused this Power of Attorney to be duly
executed as of this 30th day of August, 2018.


							/s/ Dennis McLoughlin
							Dennis McLoughlin